Compare KVUE & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KVUE | GEHC |
|---|---|---|
| Founded | 2022 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Computer Software: Prepackaged Software |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9B | 33.1B |
| IPO Year | 2023 | N/A |
| Metric | KVUE | GEHC |
|---|---|---|
| Price | $17.33 | $83.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | $20.31 | ★ $86.67 |
| AVG Volume (30 Days) | ★ 37.7M | 4.2M |
| Earning Date | 11-03-2025 | 10-29-2025 |
| Dividend Yield | ★ 4.79% | 0.17% |
| EPS Growth | ★ 35.31 | 32.35 |
| EPS | 0.75 | ★ 4.83 |
| Revenue | $15,006,000,000.00 | ★ $20,246,000,000.00 |
| Revenue This Year | N/A | $6.33 |
| Revenue Next Year | $2.81 | $4.38 |
| P/E Ratio | $23.18 | ★ $17.38 |
| Revenue Growth | N/A | ★ 3.51 |
| 52 Week Low | $14.02 | $57.65 |
| 52 Week High | $25.17 | $94.80 |
| Indicator | KVUE | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 60.90 | 61.45 |
| Support Level | $16.70 | $82.51 |
| Resistance Level | $17.59 | $86.19 |
| Average True Range (ATR) | 0.31 | 2.29 |
| MACD | 0.03 | 0.48 |
| Stochastic Oscillator | 76.29 | 77.18 |
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).